Simvastatin effects in normo- and hypercholesterolaemic patients with peripheral arterial occlusive disease: a pilot study.

Improvement of endothelial function caused by statin treatment is not related to lowering of the cholesterol levels but results primarily from statin pleiotropic effects. Accordingly, we designed a pilot study in 10 normocholesterolaemic and 10 hypercholesterolaemic patients with peripheral arterial occlusive disease to investigate potential biological effects of statins in relation to their effects on endothelial function. The patients were treated with simvastatin 40 mg/daily for 3 months.

Misoprostol as agonist of IP2 receptor.

Fourteen patients with peripheral vascular disease received 200 microg of misoprostol 3 times a day during one month. The therapy with misoprostol caused clinical and biochemical improvement in all 14 patients. An elongation of pain free and maximum walking distance, shortening of pain duration and increase in arterial blood flow in both calves were observed.

[Evaluation of fraxiparine efficacy in the treatment of retinal vein occlusion].

Purpose: To evaluate the efficacy of Fraxiparine in the treatment of central retinal vein occlusion and retinal branch vein occlusion.

Methods: 30 patients were treated. Fraxiparine (Sanofi-Pharma) was injected subcutaneously in doses of 7.

Influence of bezafibrate on total antioxidant activity of serum and deformability of blood cells in hypercholesterolaemic patients.

Fourteen patients with hypercholesterolaemia were treated with bezafibrate (600 mg/day) for a month. Before and after the treatment some biochemical and physical parameters were investigated. Plasma cholesterol levels, elevated before treatment, significantly decreased after one month (p<0.

Treatment of peripheral vascular disease with misoprostol (Cytotec): a pilot study.

Misoprostol, the oral analogue of alprostadil, was used to treat 20 patients (aged 40-60 years) with peripheral arterial disease (PAD) according to Fontaine's classification at stages IIa and IIb. All patients received 200 micrograms of misoprostol 3 times a day during a month. The therapy with misoprostol resulted in clinical improvement in all patients.